Please login to the form below

Not currently logged in
Email:
Password:

Servier defends Perindopil overcharging claim

Servier refutes claims made by the UK's Department of Health the company is overcharging for high blood pressure and heart disease drug Perindopil

Servier is contesting legal action by the UK's Department of Health (DH), which claims the French drug manufacturer charged £220m too much for its high blood pressure and heart disease drug perindopril.

A report in the UK paper, the Daily Mail, alleges that Health Secretary Andrew Lansley has accused Servier of forcing doctors to pay for expensive versions of the pills when generic ones were available.

Lansley also alleges that the company paid millions of pounds to rivals not to make generic versions, after its patent ran out in 2001, according to the report.

Lansley is leading the action at the High Court with ten strategic health authorities and 157 primary care trusts to reclaim money the NHS was overcharged between 2001 and 2007.

A spokeswoman for Servier said: "We are contesting the claim and we are confident that the right outcome will be reached."

Meanwhile a spokeswoman for the DH told PMLiVE that the department could not comment on ongoing proceedings.

Earlier this year Lansley took legal action against Reckitt Benckiser, claiming nearly £90m for overcharging for heartburn drugs.

7th June 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics